Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma
β Scribed by Danny Ka Ho Wong; Fung Yu Huang; Ching Lung Lai; Ronnie Tung Ping Poon; Wai Kay Seto; James Fung; Ivan Fan Ngai Hung; Man Fung Yuen
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 217 KB
- Volume
- 54
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
We aimed to investigate the incidence of occult hepatitis B infection (OBI) in patients with ''cryptogenic'' hepatocellular carcinoma (HCC) and to study the HBV replicative activity in these patients. Tumorous and adjacent nontumorous liver tissues were obtained from 33 cryptogenic HCC patients and 28 HCC patients with identifiable causes (13 with chronic hepatitis B [CHB], six with chronic hepatitis C, and nine alcohol-related). OBI was identified by nested polymerase chain reaction (PCR). Intrahepatic HBV DNA, covalently closed circular DNA (cccDNA), and pregenomic RNA (pgRNA) were quantified by real-time PCR and reverse-transcription PCR (RT-PCR), respectively. OBI was identified in 24 (73%) cryptogenic HCC patients, one (17%) HCC patient with HCV, and five (56%) patients with alcohol-related HCC. In HCC patients with OBI, HBV DNA were detected in !2 HBV genomic regions more often in nontumorous tissues than in tumorous tissues (90% versus 57%, respectively; P 5 0.007). Cryptogenic HCC patients with OBI had lower intrahepatic total HBV DNA levels than HCC patients with CHB (median: 0.010 versus 3.19 copies/cell, respectively; P < 0.0001). Only six (26%) cryptogenic HCC patients with OBI had detectable cccDNA (median: <0.0002 copies/cell), which was significantly lower than that of the CHB patients (median: 0.005 copies/cell; P < 0.0001). HBV pgRNA were detectable in 12 (52%) cryptogenic HCC patients with OBI (median: 0.0001 copies/cell), which was significantly lower than that of the CHB patients (median: 2.90 copies/cell; P < 0.001). Conclusion: 73% of patients with apparently unidentifiable causes for HCC were HBV-related. The detection rate was higher in nontumorous tissues than tumorous tissues. The low intrahepatic HBV DNA and pgRNA levels indicated that persistent viral replication and possibly HBV integration are the likely causes of HCC in OBI patients. (HEPATOLOGY 2011;54:829-836) See Editorial on Page 760 C hronic hepatitis B (CHB) infection with detectable circulating hepatitis B surface antigen (HBsAg) is a common cause of hepatocellular carcinoma (HCC). Approximately 60% of the world's 530,000 HCC cases per year are related to CHB. 1 The prevalence of CHB is approximately 8% in Hong Kong. 2 In Hong Kong, an endemic region for CHB, 75%-80% of the HCC cases were related to CHB infection, whereas chronic hepatitis C infection, and coinfection of hepatitis B virus (HBV) and hepatitis C virus (HCV) accounted for 3%-6% and 0.4%-3%, respectively. Alcohol-related cirrhosis accounts for another 5% of HCC cases. 3 There remains around 5% of HCC cases in which no obvious causes can be identified. Detailed studies delineating the exact cause of HCC in this group of patients are currently lacking.
During the course of CHB infection, some patients may undergo HBsAg seroclearance and have
π SIMILAR VOLUMES
## Abstract DNA of free hepatitis B viruses (HBV) has been detected in the liver of patients infected with hepatitis C virus (HCV). It is unknown whether HBV DNA is integrated into such livers; if so, it may affect hepatocarcinogenesis. Hepatocellular carcinomas (HCCs) from 34 patients without HBV
Previous studies have suggested that prior exposure to hepatitis B virus (HBV) infection may increase the risk of development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. The aim of this study was to compare the prevalence of previous or occult HBV infection in a cohort of
## Abstract Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) have similar transmission routes, implying that patients infected with HIV are at particular risk for HBV infection. Patients who are coβinfected with HIV and HBV progress more rapidly to endβstage liver disease and differen